A pharmaceutical company announced Thursday that it plans to introduce a significantly lower-cost version of Daraprim, the drug that made headlines last month after jumping from $13.50 per pill to $750.
Imprimis Pharmaceuticals is offering a "customizable compounded formulations" of the two main ingredients in Turing Pharmaceuticals' Daraprim, which is typically used to treat toxoplasmosis, an infection caused by a parasite. The drug is particularly critical for pregnant women and those infected with immunodeficiency disorders like HIV/AIDS. Their version of the pill will be available for less than a dollar per capsule, according to a press release. A 100-pill bottle will sell for as low at $99, the company said.
"While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider," said Mark L. Baum , CEO of Imprimis.
The cheap version of Daraprim is only the beginning, according to the release. The company plans to partner with third party insurers and buyers to implement a new program called Imprimis Cares that will make over 7,800 FDA-approved generic drugs available at an affordable price.